Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15082035 | 0.74 | MAP3K11 (0.43) | MAP3K11CYP11B2DRD2DRD4AR | |
| SCHEMBL12045455 | 0.74 | GSK3A (0.42) | ALDH1A1ALOX15MAPTTSHRHSP90AA1 | |
| SCHEMBL14209166 | 0.71 | DRD2 (0.49) | MAP3K11CYP11B2DRD2DRD4ALDH1A1 | |
| SCHEMBL24405711 | 0.64 | OPRM1 (0.43) | MAP3K11ARALDH1A1ALOX15GAA | |
| SCHEMBL31599423 | 0.64 | GAA (0.49) | DRD2DRD4ALDH1A1GAAMAPT | |
| SCHEMBL1997957 | 0.64 | CYP11B2 (0.44) | MAP3K11CYP11B2DRD2DRD4AR | |
| SCHEMBL26683830 | 0.64 | CRBN (0.47) | MAP3K11CYP11B2DRD2DRD4AR | |
| SCHEMBL5626795 | 0.62 | CYP11B2 (0.45) | MAP3K11CYP11B2DRD2DRD4AR | |
| SCHEMBL19872898 | 0.61 | MAPT (0.48) | CYP11B2DRD2DRD4ALDH1A1ALOX15 | |
| SCHEMBL2700854 | 0.61 | KMT2A (0.47) | DRD2DRD4ALDH1A1CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8940758-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-01-27 | — | — | US | disclosed |
| US-20130303553-A1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2013-11-14 | — | — | US | disclosed |
| US-20110319394-A1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319394-A1 | FUSED HETEROCYCLIC COMPOUNDS | PDE5A, PDE2A, PDE3A | MAP3K11 1893/4885CYP11B2 132/4885DRD2 201/4885 |
| US-20130303553-A1 | FUSED HETEROCYCLIC COMPOUNDS | PDE5A, PDE2A, PDE3A | MAP3K11 1893/4885CYP11B2 132/4885DRD2 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.